神經營養性角膜炎（NK）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 法國神經營養性角膜炎市場預計將從2025年的2,200萬美元成長到2035年的4,000萬美元。
• 推動市場成長的因素如下：
• 擴大再生醫學在眼科治療的應用
• 人們對這種疾病的認知不斷提高，早期診斷也取得了進展。
• 未來的進展取決於能夠恢復角膜神經功能並實現角膜持續癒合的治療方法。

神經營養性角膜炎（NK）概述

神經營養性角膜炎是一種罕見的退化性角膜疾病，由三叉神經支配角膜受損引起，導致角膜感覺喪失、上皮壞死和創傷治療延遲。常見原因包括皰疹性角膜炎、糖尿病和神經外科手術。隨著臨床分期的進展和角膜結構的破壞，患者會從表淺上皮損傷發展為持續性上皮缺損（PED）、基質溶解，甚至穿孔，通常表現為裂隙燈檢查時角膜觀察明顯，疼痛輕微或無疼痛。診斷依賴使用Kochet-Bonet感覺計或手動棉線試驗確認角膜感覺減退。治療遵循根據疾病分期制定的嚴格臨床流程。對於早期患者，採用非手術保守治療，使用不含防腐劑的人工淚液或自體血清滴眼液促進表面癒合。對於中度至重度病例（2期和3期），此治療方案的核心是 cenergermin，一種重組人類神經生長因子，可直接刺激上皮細胞增殖和角膜神經再生。對於難治性機械性缺損，需要採取保護措施，例如羊膜移植和眼瞼縫合。尤其重要的是，對於伴隨嚴重三叉神經損傷的晚期病例，應將角膜神經病變納入標準治療方案。這是一種特殊的外科技術，透過移植健康的感覺神經，永久恢復角膜感覺並維持長期視力。

主要亮點

• 根據預測，德國確診的神經營養性角膜炎（NK）病例數將從2025年的22,780 例增加到2035年的23,993 例。
• 神經營養性角膜炎是一種罕見的退化性角膜疾病，可導致持續性上皮缺損、角膜潰瘍和視力喪失。
• 診斷延遲和治療選擇有限仍然是重大的臨床挑戰。
• 目前，促進角膜癒合和維持視力的治療方法仍存在巨大的未滿足需求。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

形式和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東

提及的公司

• Dompe Farmaceutici SpA
• TearSolutions, Inc.
• Staidson（Beijing）Biopharmaceuticals Co., Ltd.
• ReGenTree, LLC
• Krystal Biotech, Inc.
• Claris Biotherapeutics, Inc.

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法 - 概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章 未滿足的需求與TPP分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Global Neurotrophic Keratitis (NK) Market Outlook

Thelansis's "Global Neurotrophic Keratitis (NK) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurotrophic Keratitis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Neurotrophic Keratitis (NK) Overview

Neurotrophic keratitis is a rare degenerative corneal disease caused by impairment of trigeminal corneal innervation, leading to loss of corneal sensitivity, epithelial breakdown, and poor wound healing. Common etiologies include herpetic keratitis, diabetes, and neurosurgical procedures. As the corneal architecture degrades across clinical stages, patients progress from superficial epitheliopathy to persistent epithelial defects (PEDs), stromal melting, and perforation, presenting classically with significant slit-lamp staining but minimal or no pain. Diagnosis relies on confirming reduced corneal sensitivity using a Cochet-Bonnet esthesiometer or a manual cotton wisp test. Management follows a strict stage-specific clinical algorithm. Early-stage disease is addressed with non-surgical preservation, utilizing preservative-free artificial tears and autologous serum drops to promote surface healing. For moderate-to-severe cases (Stages 2 and 3), the treatment paradigm centers on cenergermin, a recombinant human nerve growth factor that directly stimulates epithelial proliferation and corneal nerve regeneration. Refractory mechanical defects require protective interventions like amniotic membrane transplantation or tarsorrhaphy. Crucially, for advanced cases with severe trigeminal nerve damage, standard care integrates corneal neurotization-a specialized surgical technique that grafts healthy sensory nerves to permanently restore corneal sensation and maintain long-term visual acuity.

Key Highlights

• In Germany, diagnosed Neurotrophic Keratitis (NK) cases are projected to increase from 22,780 in 2025 to 23,993 by 2035.
• Neurotrophic Keratitis is a rare degenerative corneal disease that can lead to persistent epithelial defects, corneal ulcers, and vision loss.
• Delayed diagnosis and limited treatment options continue to pose significant clinical challenges.
• Significant unmet need remains for therapies that promote corneal healing and preserve vision.

Market Overview

• The France Neurotrophic Keratitis market is projected to grow from $22M in 2025 to $40M by 2035.
• Market growth is driven by:
• Increasing adoption of regenerative ophthalmic therapies
• Improved disease awareness and earlier diagnosis
• Future growth will depend on therapies capable of restoring corneal nerve function and achieving sustained corneal healing.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle Ea

Companies Mentioned

• Dompe Farmaceutici S.p.A.
• TearSolutions, Inc.
• Staidson (Beijing) Biopharmaceuticals Co., Ltd.
• ReGenTree, LLC
• Krystal Biotech, Inc.
• Claris Biotherapeutics, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)